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Transplantation of pancreatic islets for treating type 1 diabetes is
restricted to patients with critical metabolic lability resulting from the
need for immunosuppression and the shortage of donor organs. To
overcome these barriers, we developed a strategy to macroencap-
sulate islets from different sources that allow their survival and
function without immunosuppression. Here we report successful and
safe transplantation of porcine islets with a bioartificial pancreas
device in diabetic primates without any immune suppression. This
strategy should lead to pioneering clinical trials with xenotransplan-
tation for treatment of diabetes and, thereby, represents a previously
unidentified approach to efficient cell replacement for a broad
spectrum of endocrine disorders and other organ dysfunctions.
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Type 1 diabetes (T1D) is an autoimmune disease with in-creasing incidence during the last decades (1). Despite major
advances in the treatment of T1D, it is still associated with
substantial morbidities and a significant reduction in life expec-
tancy (2). The transplantation of isolated pancreatic islets is an
established therapy for a subset of patients with T1D that can
effectively restore normoglycemia, prevent hypoglycemia, and
stabilize the long-term complications of T1D (3, 4). However,
several problems prohibit this therapy from becoming more
widespread. First, there is a lack of suitable human donor organs.
Second, human islet transplantation currently requires lifelong
immunosuppression, and third, the long-term effects of the graft
are unsatisfactory because of immunological and inflammatory
reactions, which are also associated with a suboptimal microen-
vironment of the islet transplant (5).
To overcome these limitations, strategies for physical barriers
that protect transplanted cells from immune attacks have been
investigated (5–7). If successful, this would create a customized
microenvironment to facilitate survival and function of grafts and
allow a safe use of alternative cell sources such as xenogeneic
and stem cell-derived insulin-producing cells (5, 6, 8, 9).
We have previously reported a strategy for macroencapsulation of
islets that provides sufficient immune isolation and allows endoge-
nous regulation of insulin secretion (Fig. 1). This BetaO2 bio-
artificial pancreas device (10) consists of two islet compartments and
an oxygen reservoir that can be refilled through port connections
that maintain physiological oxygen pressure without direct contact
with the bloodstream. The outside of the chamber is covered with
porous membranes of hydrophilized polytetrafluoroethylene that
are impregnated with high mannuronic acid alginate to prevent
immunologic communication between the recipient and the graft
tissue (Fig. 1). In previous studies, this concept was successfully
tested in models of rat and pig xeno- and allotransplantation (10–
13). These initial studies established islet macroencapsulation as a
feasible approach to transplantation. We have also performed a
pioneer application in a patient with T1D by transplanting en-
capsulated allogeneic islets isolated from a human donor and
followed the patient over a period of 10 mo without immuno-
suppression. Viable transplanted islets were successfully retrieved
after 10 mo, and we found no evidence of an immune response
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against the transplanted islets (14). The availability of human islets
is, however, very limited. Therefore, we progressed to an alter-
native cell source of porcine islets, which is an intriguing option for
various replacement therapies in view of the consistent lack of
sufficient human organs for the increasing number of patients on
the waiting lists. In particular, given the recent prospects of devices
for safe encapsulation as presented here, xenotransplantation of-
fers a potentially unlimited source of material for islet grafts (15).
Although stem cell–derived therapies may offer great long-term
promise for diabetes therapy, xenotransplants may represent an
option with potentially shorter horizons to the clinic (16).
Results
Nonhuman Primate Model. The combination of surgical subtotal
pancreatectomy plus streptozotocin resulted in reproducibly
C-peptide-deficient recipients. Because of the insulin and gluca-
gon deficiency, the glycemic profile was highly unstable, and
complex diabetes care as practice in completely insulin-deficient
patients with diabetes was necessary to achieve acceptable control
of blood glucose (BG). As the result of an extensive training
program, to which every recipient animal was exposed before
entering the study, glucose monitoring, exogenous insulin treat-
ment, and the daily oxygen refueling of the device were performed
without complications. The animals showed adequate recovery
from the interventions, food and water intake was quickly nor-
malized, and body weight development was recorded as equivalent
to that of healthy controls (Table 1).
Metabolic Follow-Up. Graft function was evaluated by frequent BG
measurements and determination of systemic basal and stimulated
C-peptide [i.v. glucose tolerance tests (ivGTT)]. On transplantation,
the animals showed a steadily improving glycemic control (Fig. 2 A
and B), whereas insulin demand could be decreased by approxi-
mately half of pretransplantation needs (pretransplantation: 18.9 ±
1.6 IU/d; day 151–180 posttransplantation: 10.8 ± 2.4 IU/d; Table
1). This marked reduction in insulin use was not at the expense of
glycemic control, as indicated by the assessment of serum fructos-
amine levels, which are reflecting glucose levels during the previous
2–3 wk. At baseline, animals showed mean fructosamine levels of
194 ± 12 μmol/L. The normal range for this species is indicated as
160–230 μmol/L (17). All animals showed an increase in fructos-
amine levels after diabetes induction (260 ± 31 μmol/L) and a
steady decrease after transplantation reaching normal ranges at
12 wk (213 ± 12 μmol/L) and 24 wk (206 ± 8 μmol/L) after
transplantation. For the determination of direct graft function,
porcine C-peptide was measured during ivGTTs. We observed BG
kinetics comparable to healthy control animals and adequate
C-peptide secretion on glucose challenge (Fig. 2 C and D). A
summary of metabolic characteristics is provided in Table 1.
Biocompatibility and Immune Assessment. On the retrieval at 6 mo,
the device was macroscopically intact, the membrane surface was
clean and without any adhesions, and the implantation site
appeared as a thin fibrous capsule (Fig. 3) that was strongly vas-
cularized, as shown by immunohistochemical analysis for CD31
(Fig. 4 A and B). The extracted alginate-immobilized islet slabs
were analyzed immunohistochemically and revealed a well-preserved
architecture with regular distribution of cell types, as typical for
adult porcine islets (18). The explanted islet grafts showed no
morphological difference in comparison with the islets implanted
initially (Fig. 4 C and D). The surrounding tissue showed no signs
of inflammation, and immunohistochemical staining for immune
markers such as CD8, CD3, and CD68 identified only rare, ap-
parently sporadic positive cells (Fig. 4 E, F, and G).
Discussion
This encapsulation strategy was applied by us to a preclinical
model of porcine islet xenografts in diabetic nonhuman primates
(NHP). We demonstrated a comprehensive safety profile of the
xenograft in the BetaO2 bioartificial pancreas device, with no
detectable transmission of porcine cytomegalovirus or porcine
endogenous retroviruses to the NHP hosts (19) and persistent
graft function with regulated insulin secretion without any immuno-
suppressive therapy. In addition to the indirect clinical benefits
such as glycemic stability and prevention of hypoglycemia that have
been shown in other approaches (9), the detection of endogenous
porcine-specific C-peptide provided a direct proof of graft function.
The failure to achieve complete independence to insulin in our
system is certainly associated in part with the well-described limi-
tations of the NHP model (20, 21), but is also a result of the intrin-
sic limitations of any encapsulation system in which nutrient and
hormonal passage over the physical barriers are solely dependent
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Fig. 1. Schematic view of the chamber system for islet macroencapsulation and encapsulated porcine islets. (A) The system is built from two islet com-
partments containing the islets immobilized in alginate and an oxygen module in center, connected to access ports for exogenous oxygen refilling. These
ports allow direct injection of oxygen-enriched gas mixture (95% oxygen at 1.4 ATM; 1,011 Torr) into the central cavity. Oxygen is diffusing via the gas
permeable membranes into two external chambers and via additional two gas permeable membranes into the cell chambers, where it is dissolved and
consumed by the islets. According to mathematical models, refueling of oxygen every 24 h ensures minimal pO2 within the islet module at above critical value
of 60 Torr at all islets, (29). The plastic housing of the chamber is covered by porous membranes of hydrophylized polytetrafluoroethylene impregnated with
alginate. Drawing is not to scale. (B) Microscopic image (brightfield) of porcine islets immobilized in alginate ready for integration into the chamber system.
Table 1. Summary of demographic and metabolic data (n = 3)
Animal characteristics
Before
transplantation
6 mo after
transplantation
Age, y 6.4 ± 1.2 6.9 ± 1.2
Weight, kg 8.5 ± 1.4 9.0 ± 1.4
Daily insulin requirement, IU/d 18.9 ± 1.6 10.8 ± 2.4
Fasting BG, mmol/L 9.9 ± 1.7 7.8 ± 11.3
Stimulated C-peptide, ng/mL — 16.7 ± 3.0
Fructosamine, μmol/L 260 ± 31 206 ± 8
Data are shown as mean ± SD.
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on diffusion (22). The lack of insulin independence also prevents
checking the safety of the device with regard to delayed insulin
response and systemic insulin effect on glucose challenge and
consecutive hypoglycemia. However, this potential challenge of any
diffusion device has been addressed in previous studies with the
BetaO2 device (13). Also, in a single-patient study carried out with
encapsulated human islets (14), no episodes of hypoglycemia have
been detected even though the patient was temporarily substituted
with basal insulin only. Overall, the challenge of insulin secretory
kinetics using encapsulation devices is a crucial one, and because of
the critical limitations of animal models with respect to the ex-
trapolation of results to the clinical situation, it seems likely a
satisfactory answer can only be generated in clinical pilot trials. In
summary, this concept of islet macroencapsulation has previously
been successfully proven in different transplant models in small and
large animals, and now in a xenogeneic NHP model with regard to
biocompatibility, safety, efficacy, and sufficient immunoprotection.
Ongoing refinements of the device with a particular focus on in-
creasing the transplantable islet mass and optimized, simplified
approaches for oxygen supply are targeted on a larger cohort of
subjects eligible for this beta cell replacement approach. Further-
more, functional potency of porcine islets can be optimized by
pretreatment strategies such as the application of GHRH agonists
(23), which we have shown to be highly beneficial for improving
graft survival and function (11, 24–26). The coupling of bioactive
components to the device membrane surface (e.g., anti-inflammatory,
revascularization enhancing substances) might further improve
this concept. In conclusion, the described strategy is a major step
for a future curative approach to diabetes, supporting further in-
depth studies to optimize cell sources and application devices.
Importantly, it also presents a previously untried and more efficient
strategy of cell replacement for a broad spectrum of endocrine
disorders and other organ dysfunctions.
Materials and Methods
All animal studies were approved and in accordance with the strict guidelines
established by the University of Dresden Institutional Animal Care and Use
Committee and the respective authorities.
Donor Animals andOrgan Retrieval. Porcine islets were isolated fromGoettingen
minipigs (Ellegard). Before organ retrieval, the animals were housed under
standard conditions (19–23 °C; 40–70% relative humidity; 12:12 h day:night
cycle) and fed twice daily with special minipig pelleted food (Ellegard). Water
was provided ad libitum. For this study, female retired breeder minipigs with
an average age of 3–4 y and average pregnancies of three to four were used
ensuring for reproducible islet yields and quality (27). The procedure of pan-
creas organ retrieval has been described in detail previously (27). In brief, after
premedication, the anesthesia was performed as total i.v. anesthesia. After
median laparotomy, the peritoneal layer covering the pancreas was incised
and the organ was mobilized from its adjacent tissue, leaving the major
pancreas supplying vasculature intact. Organ perfusion was performed sys-
temically through a perfusion catheter inserted in the suprarenal aorta, using
cold Custodiol-HTK solution (Köhler Chemie GmbH).
Porcine Islet Isolation and Encapsulation. Islet isolation was performed by a
modified Ricordi method using collagenase NB8 (4 U/g tissue) and neutral
protease (0.6 U/g tissue) purchased from SERVA and DNase (100 mg; Roche
Diagnostics) for digestion. Purificationwasperformedbydiscontinuous gradient
centrifugation. Isolated islets were cultured in CMRL medium supplemented
with 10% heat-inactivated FBS (Gibco), and L-glutathione 32.5 mM (Sigma-
Aldrich). Islet isolation outcome was determined by assessing the number of
islet particles and their volume converted into islet equivalents, using standard
dithizone staining. The encapsulation procedure was performed 24 h after
isolation, according to our established good manufacturing practice (GMP)-like
protocols.
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Fig. 2. Efficacy study of macroencapsulated porcine islets transplanted into diabetic nonhuman primates (n = 3). (A) The levels of fasting BG showed
persistent stable glycemic control over time, despite a stepwise reduction in daily exogenous insulin dose (B). On explantation, the insulin demand imme-
diately increased to prevent hyperglycemia. Values are shown as mean (solid line) ± SD (dashed line) for all three animals. Total insulin was composed of long-
acting insulin (glargine; Lantus, Sanofi-Aventis) and short-acting insulin (glulisine; Apidra, Sanofi-Aventis). All animals were challenged by ivGTT before intervention
and 1 wk, 4 wk, 3 mo, and 6 mo after transplantation, as well as after explantation of the islet graft. (C) During glucose challenge, there was adequate BG
lowering comparable to healthy control, accompanied by porcine-specific C-peptide secretion (D). (Insets) AUC for BG (mmol × min × L−1) and porcine
C-peptide (ng × min × mL−1) during the glucose challenge for each time.
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Bioartificial Pancreas Device. The detailed construction of the chamber system
used for islet macroencapsulation was previously described (10–13). Briefly,
the device is 68 mm in diameter and 18 mm in thickness (Fig. 1), composed
of a 600-μm-thick immobilized islets module attached to an oxygen module
by a gas-permeable silicon-rubber membrane. The oxygen module is con-
nected to two polyurethane access ports implanted s.c. A gas mixture
containing 95% O2 at 1.4 atm and 5% CO2 is refilled daily. The outside of
the chamber consists of hydrophilic 0.4 μm porous polytetrafluoroethylene
membranes and is impregnated with high mannuronic acid alginate
to prevent immunologic communication between the recipient and the
graft tissue.
Diabetes Induction in Recipient Animals. Rhesus macaques (Macaca mulatta) of
∼10 kg body weight were used for these studies that were performed entirely
at the German Primate Center, Göttingen, Germany. Before entering the
study, the animals were extensively trained for BG monitoring and the nec-
essary oxygen refueling of the device. For surgical diabetes induction, the
animals were fasted overnight with free access to water. After premedication,
the anesthesia was performed as total i.v. anesthesia. The abdominal region
was cleaned and shaved before disinfection and covered with surgical drapes.
After median laparotomy, the pancreas was carefully dissected from the sur-
rounding tissue and liberated. Particular precaution was exercised in the du-
odenal part of the pancreas, preserving the duodenal vascular arcade and
thereby preventing ischemic complications. Therefore, a very small part of
pancreatic tissue was left in situ. Furthermore, this strategy of subtotal pan-
createctomy allowed for preserving the anatomical drainage of the bile duct.
The abdomen and the skin were sutured with absorbable material. Post-
operatively, insulin therapy was started by multiple daily injection of insulin
(long-acting insulin glargine: Lantus, Sanofi-Aventis; short-acting insulin glu-
lisine: Apidra, Sanofi-Aventis) according to clinical practice. Insulin glargine
was given twice daily for ensuring persistent basal insulin levels at a total dose
of ∼1 IU/kg body weight (BW). Dose was adjusted to reach fasting BG levels
between 4 and 10 mmol/L. Insulin glulisine was administered before feeding
and for correcting hyperglycemia according to BG readings (2–4 IU/regular
meal; 1 IU for lowering BG by 1 mmol/L; target BG level of 8 mmol/L). One
week after pancreatectomy, the animals received a single dose of streptozo-
tocin of 80 mg/kg BW to induce complete insulin deficiency (28), which was
proven by negative monkey-specific C-peptide measurement during ivGTT.
Transplantation of Encapsulated Animals. Diabetic rhesus macaques were then
transplanted using ∼20,000 islets/kg BW, encapsulated within the BetaO2
bioartificial pancreas device, and followed for 6 mo (n = 3). After premed-
ication and establishment of anesthesia, a median relaparotomy was per-
formed and the device containing the islet graft was implantedwithin a bluntly
dissected pocket between the parietal peritoneum and the fascia of the ab-
dominal muscles. The port connections for refueling of oxygenwere placed and
fixed s.c. in the lateral thoracic region (Fig. 3). The entire study was performed
without immunosuppression.
MetabolicMonitoring. Formetabolic assessment, BG levelswere closelymonitored
and exogenous insulin treatment adjusted accordingly. Basal and short-acting
insulin doses were reduced subtly, ensuring continuous acceptable glycemic
control and avoiding induction of hypoglycemia. Concomitantly, serum samples
were takenbefore intervention, at the timeof transplantation, 1, 4, 12, and24wk
after transplantation for determination of fructosamine as marker for glycemic
control (cobas 8000, fructosamine immunoassay; RocheDiagnostics). ivGTTswere
conducted at regular intervals before intervention, after 1 and 4 wk, 3 mo, and
6moafter transplantation, aswell as after explantationof the islet graft. Samples
were takenat 5, 10, 20, 40, 60, and120min after glucose challenge andmeasured
Fig. 3. Implantable device containing porcine islets. (A) Intraoperative situs with the device, embedded in a bluntly dissected pocket between the parietal
peritoneum and the fascia of the abdominal muscles and s.c. fixed port connections for oxygen refueling. (B and C) Smooth explantation of device and port
system without relevant fibrous adhesions. (D) Retrieved bioartificial pancreas device with intact and clean membrane surfaces.
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for glucose and porcine-specific C-peptide (10-1256-01 porcine C-peptide ELISA
immunoassay; Mercodia). The ELISAwas performed according to manufacturer’s
instructions.
Immunohistochemical Analysis. After retrieval of the device, islet grafts and
the surrounding tissue were fixed overnight in 4% paraformaldehyde and
embedded in Tissue-Tek O.C.T (Sakura Finetek). Immunohistochemistry was
Fig. 4. Immunohistochemical analysis of islets after explantation and device surrounding tissue. (A and B) Representative images of tissue surrounding the
device on the peritoneal site, stained for CD31 to visualize strong vascularization as crucial for exchange of glucose/hormones. (Red) CD31, (blue) DAPI. (C and
D) Representative images of porcine islets immobilized in alginate analyzed after explantation of the device at 6 mo. (Green) insulin, (red) Glucagon, (blue)
DAPI. The architecture and cell composition of explanted islet grafts were not different to the structure at the time of implantation. Although beta cells are
often found as single cells or grouped together to form the core of islets at younger age, the retired breeder animals as used in this study typically show a
rather compact structure with beta cells scattered throughout the islet and alpha cells predominantly in the periphery. For analysis of local immune reactions
at the transplantation site, the surrounding tissue was stained for CD8+ T-cells (E), CD3+ activated cytotoxic T-cells (F), and CD68+ macrophages (G); (red)
respective CD-molecules, (blue) DAPI. Arrows indicate the relevant structures in the respective images (exemplary).
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performed on 6-μm sections using primary antibodies Guinea pig poly-
clonal anti-insulin antibody (1:100, ab7842; abcam), mouse monoclonal
anti-glucagon antibody (1:2,000, G2654; Sigma), rabbit anti-CD3 (1:100,
C7930; Sigma), mouse monoclonal anti CD4 antibody (4B12; 1:100,
MA5-12259; Thermo Fisher Scientific), rabbit monoclonal anti-CD8(SP16)
antibody (1:100, SAB5500074; Sigma), and mouse monoclonal anti CD68
Antibody (KP1; 1:100, MA5-13324; Thermo Fisher Scientific). After blocking
unspecific antibody binding sites with background sniper (Biocare medical)
for 11 min at room temperature, sections were incubated with primary
antibodies overnight at 4 °C. After washing in PBS with 0.5% Tween,
secondary antibodies goat anti-guinea pig Alexa Flour 488 (1:1,000,
A11073; Life Technologies), goat anti-rabbit Alexa Flour 568 (1:1,000,
A11011; Life Technologies), and goat anti-mouse Alexa Flour 568 (1:1,000,
A11031; Life Technologies) were applied for 1 h at room temperature.
DAPI (10236276001; Roche) was applied for cell nucleus-specific staining.
Immunofluorescence microscopy was performed on Zeiss Axiovert200M
with AxioCamMRc5.
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